RxDoctor Payments Data

James Shoptaw Jr, MD

Thoracic Surgery (Cardiothoracic Vascular Surgery) · Hazard, KYNPI 1710951942

Payments from drug & device makers

$2,618in general payments, 2019–2025

Across 112 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$503
  • Atricure, Inc.$300
  • Covidien LP$218
  • Medtronic$163
  • E.r. Squibb & Sons, L.L.C.$159
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$115
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$2,618100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,618 in reported general payments places this provider in the 20th percentile of 98 thoracic surgery (cardiothoracic vascular surgery) providers in Kentucky.

See all thoracic surgery (cardiothoracic vascular surgery) providers in Kentucky

Medicare billing

Part B allowed, 2024
$18,283
Medicare patients
68
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$11,226
XareltoRivaroxaban12$7,583
ClopidogrelClopidogrel Bisulfate90$668
Atorvastatin Calcium30$142
FenofibrateFenofibrate Nanocrystallized12$140
Rosuvastatin Calcium17$137
Metoprolol Tartrate49$127
Metoprolol Succinate14$66
Gabapentin11$58
Pantoprazole Sodium14$40
Amlodipine Besylate12$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$11,22618 claims
Johnson & JohnsonXarelto$110$7,58312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 98 thoracic surgery (cardiothoracic vascular surgery) providers in Kentucky.

Other thoracic surgery (cardiothoracic vascular surgery) in Hazard

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →